Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:IDYANASDAQ:SDGRNASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$65.12-1.3%$62.15$52.50▼$70.00$1.42B0.49266,954 shs383,752 shsIDYAIDEAYA Biosciences$15.77-0.1%$19.17$13.45▼$44.42$1.38B0.51920,747 shs2.52 million shsSDGRSchrödinger$19.22-1.5%$21.99$16.60▼$28.47$1.40B1.77779,086 shs1.24 million shsSNDLSNDL$1.37-1.4%$1.60$1.26▼$2.93$360.00M3.232.67 million shs904,347 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+4.69%-4.83%+12.24%+21.88%-1.55%IDYAIDEAYA Biosciences+8.83%-3.49%-10.03%-36.50%-62.93%SDGRSchrödinger+8.63%-1.81%-2.20%-3.98%-31.51%SNDLSNDL+9.45%-3.47%-7.95%-26.06%-33.49%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.5564 of 5 stars2.51.00.03.33.33.31.3IDYAIDEAYA Biosciences3.3319 of 5 stars3.50.00.04.43.41.70.0SDGRSchrödinger2.7487 of 5 stars3.52.00.00.04.02.50.6SNDLSNDL3.5273 of 5 stars3.55.00.00.03.10.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$79.7522.47% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$53.58239.78% UpsideSDGRSchrödinger 3.00Buy$32.2967.98% UpsideSNDLSNDL 3.00Buy$3.63164.60% UpsideCurrent Analyst Ratings BreakdownLatest SNDL, ANIP, SDGR, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025SNDLSNDLATB CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price Target$3.50 ➝ $4.003/17/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.003/14/2025ANIPANI PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.003/12/2025ANIPANI PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.003/5/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$84.00 ➝ $86.003/3/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.002/27/2025SDGRSchrödingerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.002/14/2025IDYAIDEAYA BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.001/24/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $27.001/15/2025IDYAIDEAYA BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$61.00 ➝ $61.001/13/2025IDYAIDEAYA BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.31$7.21 per share9.03$21.13 per share3.08IDYAIDEAYA Biosciences$7M197.21N/AN/A$12.10 per share1.30SDGRSchrödinger$207.54M6.76$0.51 per share37.42$7.60 per share2.53SNDLSNDL$920.45M0.39N/AN/A$3.47 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$18.78M-$1.14N/A15.47N/A-1.28%15.87%6.88%5/9/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.30N/AN/AN/AN/A-26.74%-25.54%5/6/2025 (Estimated)SDGRSchrödinger$40.72M-$2.57N/AN/AN/A-91.84%-35.77%-24.51%4/29/2025 (Estimated)SNDLSNDL-$127.91M-$0.26N/AN/AN/A-12.11%-8.27%-6.96%5/14/2025 (Estimated)Latest SNDL, ANIP, SDGR, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75N/AN/AN/A$2.10 millionN/A4/29/2025Q1 2025SDGRSchrödinger-$0.81N/AN/AN/A$54.60 millionN/A3/18/2025Q4 2024SNDLSNDL-$0.01-$0.19-$0.18-$0.19$248.10 million$179.06 million2/26/2025Q4 2024SDGRSchrödinger-$0.35-$0.55-$0.20-$0.55$83.20 million$88.32 million2/13/2025Q4 2024IDYAIDEAYA Biosciences-$0.67-$1.49-$0.82-$1.49$7.00 million$7.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.522.741.97IDYAIDEAYA BiosciencesN/A14.9722.93SDGRSchrödingerN/A4.114.11SNDLSNDL0.105.614.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%IDYAIDEAYA Biosciences98.29%SDGRSchrödinger79.05%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%IDYAIDEAYA Biosciences3.50%SDGRSchrödinger8.60%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.77 million18.36 millionOptionableIDYAIDEAYA Biosciences8087.54 million84.47 millionOptionableSDGRSchrödinger79073.04 million66.59 millionOptionableSNDLSNDL580262.78 millionN/AOptionableSNDL, ANIP, SDGR, and IDYA HeadlinesRecent News About These CompaniesSNDL pays CA$32.2M for 32 cannabis stores in 3 Canadian provincesApril 10 at 1:27 PM | mjbizdaily.comSNDL Inc. (NASDAQ:SNDL) Shares Bought by Cannell Capital LLCApril 10 at 7:12 AM | marketbeat.comSNDL to acquire Cost Cannabis and T Cannabis locations from 1CMApril 10 at 3:25 AM | markets.businessinsider.comSNDL buys Cost Cannabis and T Cannabis for C$32 millionApril 9 at 5:14 PM | greenmarketreport.comSNDL Expands Cannabis Retail Footprint With C$32.2M Acquisition of 1CM StoresApril 9 at 5:14 PM | marketwatch.comSNDL Expands Canadian Retail Presence with Acquisition of 1CM StoresApril 9 at 9:17 AM | tipranks.comSNDL Expands Canadian Retail Footprint with Acquisition of 1CM StoresApril 9 at 9:17 AM | tipranks.comSNDL Enters into Agreement to Acquire Cost Cannabis and T Cannabis Locations from 1CMApril 9 at 8:39 AM | prnewswire.comSNDL Enters into Agreement to Acquire Cost Cannabis and T Cannabis Locations from 1CMApril 9 at 8:39 AM | prnewswire.comSNDL Enters into Agreement to Acquire Cost Cannabis and T Cannabis Locations from 1CMApril 9 at 8:15 AM | newsfilecorp.comSNDL Enters into Agreement to Acquire Cost Cannabis and T Cannabis Locations from 1CMApril 9 at 8:15 AM | newsfilecorp.comTop Canadian Cannabis Stocks to Watch in April 2025March 30, 2025 | marijuanastocks.comFY2025 Earnings Forecast for SNDL Issued By Atb Cap MarketsMarch 22, 2025 | marketbeat.comQ1 Earnings Forecast for SNDL Issued By Atb Cap MarketsMarch 21, 2025 | marketbeat.comATB Capital Forecasts Strong Price Appreciation for SNDL (NASDAQ:SNDL) StockMarch 20, 2025 | marketbeat.comSNDL Inc. (NASDAQ:SNDL) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comSNDL Full Year 2024 Earnings: EPS Misses ExpectationsMarch 19, 2025 | finance.yahoo.comSNDL Stock: Despite The Weakness In Cannabis Sector, I Maintain My Buy RatingMarch 19, 2025 | seekingalpha.com3 Canadian Marijuana Stocks To Watch For Future Gains 2025March 19, 2025 | marijuanastocks.comSNDL (NASDAQ:SNDL) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPSMarch 19, 2025 | marketbeat.comSNDL Inc. Reports Record Revenue and Strategic MovesMarch 19, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDL, ANIP, SDGR, and IDYA Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$65.12 -0.89 (-1.35%) Closing price 04:00 PM EasternExtended Trading$68.53 +3.41 (+5.24%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.IDEAYA Biosciences NASDAQ:IDYA$15.77 -0.01 (-0.06%) Closing price 04:00 PM EasternExtended Trading$15.77 0.00 (0.00%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Schrödinger NASDAQ:SDGR$19.22 -0.30 (-1.54%) Closing price 04:00 PM EasternExtended Trading$22.26 +3.05 (+15.84%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.SNDL NASDAQ:SNDL$1.37 -0.02 (-1.44%) Closing price 04:00 PM EasternExtended Trading$1.36 -0.01 (-0.73%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Delta, Walmart Cut Profit Targets: Could Start Domino Effect Joby Aviation: Operational Momentum vs. Market Sentiment Carvana: Can Turnaround Strength Outdrive Market Headwinds? Is Alphabet a Generational Buying Opportunity at These Levels? Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
